These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29157782)

  • 21. Identification of recombinant human EPO variants in greyhound plasma and urine by ELISA, LC-MS/MS and western blotting: a comparative study.
    Timms M; Steel R; Vine J
    Drug Test Anal; 2016 Feb; 8(2):164-76. PubMed ID: 26290355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of a dual-wavelength size exclusion HPLC method with improved sensitivity to detect protein aggregates and its use to better characterize degradation pathways of an IgG1 monoclonal antibody.
    Bond MD; Panek ME; Zhang Z; Wang D; Mehndiratta P; Zhao H; Gunton K; Ni A; Nedved ML; Burman S; Volkin DB
    J Pharm Sci; 2010 Jun; 99(6):2582-97. PubMed ID: 20039394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A validated stability-indicating RP-HPLC method for levofloxacin in the presence of degradation products, its process related impurities and identification of oxidative degradant.
    Lalitha Devi M; Chandrasekhar KB
    J Pharm Biomed Anal; 2009 Dec; 50(5):710-7. PubMed ID: 19632800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of culture temperature on erythropoietin production and glycosylation in a perfusion culture of recombinant CHO cells.
    Ahn WS; Jeon JJ; Jeong YR; Lee SJ; Yoon SK
    Biotechnol Bioeng; 2008 Dec; 101(6):1234-44. PubMed ID: 18980186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A validated stability-indicating LC method for acetazolamide in the presence of degradation products and its process-related impurities.
    Srinivasu P; Subbarao DV; Vegesna RV; Sudhakar Babu K
    J Pharm Biomed Anal; 2010 May; 52(1):142-8. PubMed ID: 20053517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
    Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
    Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and validation of a stability-indicating RP-HPLC assay method and stress degradation studies on dapiprazole.
    Ramesh T; Rao PN
    J Chromatogr Sci; 2013 Oct; 51(9):856-60. PubMed ID: 23169931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and validation of a stability-indicating RP-HPLC method for the simultaneous estimation of process related impurities and degradation products of rasagiline mesylate in pharmaceutical formulation.
    Reddy PS; Sudhakar Babu K; Kumar N
    J Chromatogr Sci; 2013 Mar; 51(3):242-9. PubMed ID: 22988002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validated stability-indicating HPLC method for the determination of dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate (DDB) and its degradation products.
    Hadad GM
    J Pharm Biomed Anal; 2008 Aug; 47(4-5):695-703. PubMed ID: 18403161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term stabilization of a new freeze-dried and albumin-free formulation of recombinant human interferon alpha 2b.
    Ruiz L; Reyes N; Sotolongo J; Aroche K; Aldana R; Báez R; Hardy E
    PDA J Pharm Sci Technol; 2006; 60(1):72-8. PubMed ID: 17089680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determination of KRN321 in rat serum by ELISA and correlation between ELISA and in vitro bioassay.
    Yoshioka E; Kato K; Tanabe M; Misaizu T; Ogata H
    J Immunoassay Immunochem; 2006; 27(3):265-77. PubMed ID: 16827228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stability of trastuzumab during nanomedicine formulation using SEC-HPLC coupled with polyacrylamide gel electrophoresis.
    Gao Y; Shelling AN; Porter D; Leung E; Wu Z
    Pharm Dev Technol; 2023; 28(3-4):288-298. PubMed ID: 36912800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis.
    Li WY; Chu TS; Huang JW; Wu MS; Wu KD
    J Formos Med Assoc; 2008 Nov; 107(11):843-50. PubMed ID: 18971153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A stability-indicating HPLC assay with diode array detection for the determination of a benzylpenicillin prodrug in aqueous solutions.
    Jain R; Wu Z; Tucker IG
    J Pharm Biomed Anal; 2009 Dec; 50(5):841-6. PubMed ID: 19640667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.
    Otsuka T; Sakai Y; Yui S; Sukegawa M; Suzuki A; Mugishima K; Sumi Y; Otsuka Y; Tsuruoka S
    J Nippon Med Sch; 2015; 82(1):21-6. PubMed ID: 25797871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A validated stability-indicating HPLC method for the determination of PEGylated puerarin in aqueous solutions.
    Liu X; Yu B; Wang N; Zhang B; Du F; He C; Ye Z
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Aug; 878(23):2061-6. PubMed ID: 20580327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and validation of a stability-indicating HPLC-UV method for the determination of Thiocolchicoside and its degradation products.
    Aprile S; Canavesi R; Bianchi M; Grosa G; Del Grosso E
    J Pharm Biomed Anal; 2017 Jan; 132():66-71. PubMed ID: 27697571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A critical evaluation of Tm(FTIR) measurements of high-concentration IgG1 antibody formulations as a formulation development tool.
    Matheus S; Mahler HC; Friess W
    Pharm Res; 2006 Jul; 23(7):1617-27. PubMed ID: 16783474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The oxidation of methionine-54 of epoetinum alfa does not affect molecular structure or stability, but does decrease biological activity.
    Labrenz SR; Calmann MA; Heavner GA; Tolman G
    PDA J Pharm Sci Technol; 2008; 62(3):211-23. PubMed ID: 18661870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinetics of pramlintide degradation in aqueous solution as a function of temperature and pH.
    Kenley RA; Tracht S; Stepanenko A; Townsend M; L'Italien J
    AAPS PharmSciTech; 2000 Mar; 1(2):E7. PubMed ID: 14727840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.